Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
Go back to Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension| (NASDAQ: TBPH) | Delayed: 17.04 +0.01 (0.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.03 | 52 Week High | $38.92 | |||
| Open | $17.04 | 52 Week Low | $12.87 | |||
| Day High | $17.04 | P/E | N/A | |||
| Day Low | $17.02 | EPS | $0.00 | |||
| Volume | 306,992 | |||||
